Literature DB >> 24982065

Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections.

Rujipas Sirijatuphat1, Visanu Thamlikitkul2.   

Abstract

Ninety-four patients infected with carbapenem-resistant Acinetobacter baumannii were randomized to receive colistin alone or colistin plus fosfomycin for 7 to 14 days. The patients who received combination therapy had a significantly more favorable microbiological response and a trend toward more favorable clinical outcomes and lower mortality than those who received colistin alone. (This study has been registered at ClinicalTrials.gov under registration no. NCT01297894.).
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24982065      PMCID： PMC4135862          DOI： 10.1128/AAC.02435-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues.

Authors:  M Frossard; C Joukhadar; B M Erovic; P Dittrich; P E Mrass; M Van Houte; H Burgmann; A Georgopoulos; M Müller
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia.

Authors:  Doo Ryeon Chung; Jae-Hoon Song; So Hyun Kim; Visanu Thamlikitkul; Shao-Guang Huang; Hui Wang; Thomas Man-Kit So; Rohani M D Yasin; Po-Ren Hsueh; Celia C Carlos; Li Yang Hsu; Latre Buntaran; M K Lalitha; Min Ja Kim; Jun Yong Choi; Sang Il Kim; Kwan Soo Ko; Cheol-In Kang; Kyong Ran Peck
Journal:  Am J Respir Crit Care Med       Date:  2011-09-15       Impact factor: 21.405

3.  Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients.

Authors:  S M Garonzik; J Li; V Thamlikitkul; D L Paterson; S Shoham; J Jacob; F P Silveira; A Forrest; R L Nation
Journal:  Antimicrob Agents Chemother       Date:  2011-05-09       Impact factor: 5.191

4.  Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration.

Authors:  Roberto Imberti; Maria Cusato; Paola Villani; Livio Carnevale; Giorgio A Iotti; Martin Langer; Mario Regazzi
Journal:  Chest       Date:  2010-06-17       Impact factor: 9.410

5.  Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand.

Authors:  Pornpan Koomanachai; Surapee Tiengrim; Pattarachai Kiratisin; Visanu Thamlikitkul
Journal:  Int J Infect Dis       Date:  2007-02-08       Impact factor: 3.623

6.  Risk factors for treatment failure in patients with ventilator-associated pneumonia receiving appropriate antibiotic therapy.

Authors:  Gul Gursel; Muge Aydogdu; Ezgi Ozyilmaz; Turkan N Ozis
Journal:  J Crit Care       Date:  2008-03       Impact factor: 3.425

Review 7.  Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies.

Authors:  Matthew E Falagas; Antonia C Kastoris; Drosos E Karageorgopoulos; Petros I Rafailidis
Journal:  Int J Antimicrob Agents       Date:  2009-04-28       Impact factor: 5.283

Review 8.  Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies.

Authors:  N Petrosillo; E Ioannidou; M E Falagas
Journal:  Clin Microbiol Infect       Date:  2008-09       Impact factor: 8.067

9.  Fosfomycin kinetics after intravenous and oral administration to human volunteers.

Authors:  M Goto; M Sugiyama; S Nakajima; H Yamashina
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

Review 10.  Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.

Authors:  Rinaldo Bellomo; Claudio Ronco; John A Kellum; Ravindra L Mehta; Paul Palevsky
Journal:  Crit Care       Date:  2004-05-24       Impact factor: 9.097
View more
  44 in total

Review 1.  Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.

Authors:  Nadim G El Chakhtoura; Elie Saade; Alina Iovleva; Mohamad Yasmin; Brigid Wilson; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2018-01-16       Impact factor: 5.091

2.  Fulminant endocarditis and disseminated infection caused by carbapenem-resistant Acinetobacter baumannii in a renal-pancreas transplant recipient.

Authors:  G Patel; F Perez; A M Hujer; S D Rudin; J J Augustine; G H Jacobs; M R Jacobs; R A Bonomo
Journal:  Transpl Infect Dis       Date:  2015-02-06       Impact factor: 2.228

Review 3.  Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options.

Authors:  Yohei Doi; Gerald L Murray; Anton Y Peleg
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

4.  Pharmacodynamics of colistin and fosfomycin: a 'treasure trove' combination combats KPC-producing Klebsiella pneumoniae.

Authors:  Miao Zhao; Zackery P Bulman; Justin R Lenhard; Michael J Satlin; Barry N Kreiswirth; Thomas J Walsh; Amanda Marrocco; Phillip J Bergen; Roger L Nation; Jian Li; Jing Zhang; Brian T Tsuji
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

5.  Colistin combination therapy improves microbiologic cure in critically ill patients with multi-drug resistant gram-negative pneumonia.

Authors:  N L Parchem; K A Bauer; C H Cook; J E Mangino; C D Jones; K Porter; C V Murphy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-05-26       Impact factor: 3.267

6.  Task force on management and prevention of Acinetobacter baumannii infections in the ICU.

Authors:  José Garnacho-Montero; George Dimopoulos; Garyphallia Poulakou; Murat Akova; José Miguel Cisneros; Jan De Waele; Nicola Petrosillo; Harald Seifert; Jean François Timsit; Jordi Vila; Jean-Ralph Zahar; Matteo Bassetti
Journal:  Intensive Care Med       Date:  2015-10-05       Impact factor: 17.440

7.  Simultaneously inhibiting undecaprenyl phosphate production and peptidoglycan synthases promotes rapid lysis in Escherichia coli.

Authors:  Matthew A Jorgenson; William J MacCain; Bernadette M Meberg; Suresh Kannan; Joseph C Bryant; Kevin D Young
Journal:  Mol Microbiol       Date:  2019-05-06       Impact factor: 3.501

Review 8.  Polymyxin Resistance in Gram-negative Pathogens.

Authors:  Pavithra Srinivas; Kaitlyn Rivard
Journal:  Curr Infect Dis Rep       Date:  2017-09-11       Impact factor: 3.725

9.  Evaluation of the Bactericidal Activity of Fosfomycin in Combination with Selected Antimicrobial Comparison Agents Tested against Gram-Negative Bacterial Strains by Using Time-Kill Curves.

Authors:  Robert K Flamm; Paul R Rhomberg; Jill M Lindley; Kim Sweeney; E J Ellis-Grosse; Dee Shortridge
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 10.  Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.

Authors:  J Alexander Viehman; M Hong Nguyen; Yohei Doi
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.